Cardiovascular outcomes with angiotensin II receptor blockers: Clinical implications of recent trials

6Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk. © 2011 Baumhäkel and Böhm, publisher and licensee Dove Medical Press Ltd.

Cite

CITATION STYLE

APA

Baumhäkel, M., & Böhm, M. (2011). Cardiovascular outcomes with angiotensin II receptor blockers: Clinical implications of recent trials. Vascular Health and Risk Management. DOVE Medical Press Ltd. https://doi.org/10.2147/VHRM.S17168

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free